Trial · NCT02520102
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients who develop antibodies (binding antibodies and neutralizing antibodies) | 1 month after 1st dose of sargramostim | |
| Primary | Proportion of patients who develop antibodies (binding antibodies and neutralizing antibodies) | 2 months after 1st dose of sargramostim | |
| Primary | Proportion of patients who develop antibodies (binding antibodies and neutralizing antibodies) | 3 months after 1st dose of sargramostim | |
| Primary | Proportion of patients who develop antibodies (binding antibodies and neutralizing antibodies) | 6 months after 1st dose of sargramostim. If positive at month 6, this will be continued every 6 months until the values return to baseline or up to 24 months | |
| Secondary | Assessment of antibodies (antibody detection and antibody titers) | 1 month after 1st dose of sargramostim | |
| Secondary | Assessment of antibodies (antibody detection and antibody titers) | 2 months after 1st dose of sargramostim | |
| Secondary | Assessment of antibodies (antibody detection and antibody titers) | 3 months after 1st dose of sargramostim | |
| Secondary | Assessment of antibodies (antibody detection and antibody titers) | 6 months after 1st dose of sargramostim. If positive at month 6, this will be continued every 6 months until the values return to baseline up to 24 months | |
| Secondary | Assessment of immunoglobulin levels | 1 month after 1st dose of sargramostim | |
| Secondary | Assessment of immunoglobulin levels | 2 months after 1st dose of sargramostim | |
| Secondary | Assessment of immunoglobulin levels | 3 months after 1st dose of sargramostim | |
| Secondary | Assessment of immunoglobulin levels | 6 months after 1st dose of sargramostim. If antibodies are positive at month 6, the level of immunoglubolins will be assesed every 6 months until the antibodies level return to baseline or up to 24 months | |
| Secondary | Proportion of patients with adverse events | Up to 24 months | |
| Secondary | Duration of neutropenia (time from initiation of sargramostim to recovery of ANC to ≥1500/mm^3) | Up to 42 days after first day of sargramostim administration |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02520102/registered